Skip to main content
Top
Published in: Indian Journal of Pediatrics 5/2017

01-05-2017 | Review Article

Management of Non-Hodgkin Lymphoma: ICMR Consensus Document

Authors: Nirav Thacker, Sameer Bakhshi, Girish Chinnaswamy, Tushar Vora, Maya Prasad, Deepak Bansal, Sandeep Agarwala, Gauri Kapoor, Venkatraman Radhakrishnan, Siddharth Laskar, Tanvir Kaur, G. K. Rath, Rupinder Singh Dhaliwal, Brijesh Arora

Published in: Indian Journal of Pediatrics | Issue 5/2017

Login to get access

Abstract

Hitherto poor outcomes, paucity of data and heterogeneity in International approach to Pediatric NHL (Non-Hodgkin Lymphoma) prompted the need for guidelines for Indian population with vast variability in access, affordability and infrastructure across the country. These guidelines are based on consensus among the experts and best available evidence applicable to Indian setting. Evaluation of NHL should consist of easily doable and rapid tissue diagnosis (biopsy or flow cytometry of peripheral blood/malignant effusions), St Jude/IPNHLSS (International Pediatric Non-Hodgkin Lymphoma Staging System) and risk grouping with CSF (Cerebro-spinal fluid), bone marrow, whole body imaging [CECT (Contrast enhanced computerized tomography) ± MRI (Magnetic resonance imaging)] and blood investigations for LDH (Lactate dehydrogenase), TLS (Tumor lysis syndrome) and organ functions. Life threatening complications like SVCS (Superior vena cava syndrome)/Mediastinal syndrome and TLS need to pre-empted and promptly managed. All children with poor general condition, co-morbidities, metabolic or obstructive complications should receive a steroid or chemotherapy pro-phase first. For mature B-NHL (B cell – Non-Hodgkin lymphoma), in centres with good infrastructure and methotrexate levels, FAB-LMB-96 (French-American-British/Lymphomes Malins B) or BFM (Berlin-Frankfurt-Münster)-NHL-95 protocols may be used. In centres with limited infrastructure and/or no methotrexate levels; CHOP (Cyclophosphamide-hydroxydaunomycin-oncovin-prednisolone) (early stage) or MCP (Multi-centre protocol)-842 [all stages except CNS (Central nervous system) disease] may be used. Patients with poor early response should have escalated therapy. High-Risk B-NHL will benefit with addition of Rituximab to standard chemotherapy. Radiotherapy (RT) is not warranted. For lymphoblastic lymphoma, in centres with good infrastructure and methotrexate levels, BFM-95 protocol may be used. In centres with limited infrastructure and/or no methotrexate levels; modified MCP-841 with cytarabine, modified BFM-90 protocol with reduced-dose methotrexate or I-BFM 2009 protocol using Capizzi methotrexate may be considered. For ALCL (Anaplastic large cell lymphoma), in centres with good infrastructure and methotrexate levels, ALCL-99 protocol may be considered. In centres with limited infrastructure and/or no methotrexate levels; CHOP (limited-stage only), modified MCP-842 protocol or APO (Adriamycin-prednisolone-oncovin) regimen may be used.
Literature
1.
go back to reference Kulkarni KP, Arora RS, Arora B. Current outcomes of childhood Non Hodgkin lymphoma in India: results of a systematic review. Abstracts of the 45th Congress of the International Society of Paediatric Oncology (SIOP) 2013. Hong Kong, China. September 25–28, 2013.Pediatr Blood Cancer. 2013;60:S80. Abstract nr P-0110. Kulkarni KP, Arora RS, Arora B. Current outcomes of childhood Non Hodgkin lymphoma in India: results of a systematic review. Abstracts of the 45th Congress of the International Society of Paediatric Oncology (SIOP) 2013. Hong Kong, China. September 25–28, 2013.Pediatr Blood Cancer. 2013;60:S80. Abstract nr P-0110.
2.
go back to reference Arora RS, Eden TO, Kapoor G. Epidemiology of childhood cancer in India. Indian J Cancer. 2009;46:264–73.CrossRefPubMed Arora RS, Eden TO, Kapoor G. Epidemiology of childhood cancer in India. Indian J Cancer. 2009;46:264–73.CrossRefPubMed
4.
go back to reference Naresh KN, Srinivas V, Soman CS. Distribution of various subtypes of non-Hodgkin’s lymphoma in India: a study of 2773 lymphomas using R.E.A.L. and WHO classifications. Ann Oncol. 2000;11:S63–7.CrossRef Naresh KN, Srinivas V, Soman CS. Distribution of various subtypes of non-Hodgkin’s lymphoma in India: a study of 2773 lymphomas using R.E.A.L. and WHO classifications. Ann Oncol. 2000;11:S63–7.CrossRef
5.
go back to reference Murphy SB, Fairclough DL, Hutchison RE, Berard CW. Non-Hodgkin's lymphomas of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Oncol. 1989;7:186–93.CrossRefPubMed Murphy SB, Fairclough DL, Hutchison RE, Berard CW. Non-Hodgkin's lymphomas of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Oncol. 1989;7:186–93.CrossRefPubMed
6.
7.
go back to reference Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109:2773–80.PubMedPubMedCentral Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109:2773–80.PubMedPubMedCentral
8.
go back to reference Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109:2736–43.PubMedPubMedCentral Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109:2736–43.PubMedPubMedCentral
9.
go back to reference Gerrard M, Cairo MS, Weston C, et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Br J Haematol. 2008;141:840–7.CrossRefPubMed Gerrard M, Cairo MS, Weston C, et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Br J Haematol. 2008;141:840–7.CrossRefPubMed
10.
go back to reference Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the berlin-Frankfurt-Münster group trial NHL-BFM 90. Blood. 1999;94:3294–306.PubMed Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the berlin-Frankfurt-Münster group trial NHL-BFM 90. Blood. 1999;94:3294–306.PubMed
11.
go back to reference Le Deley MC, Reiter A, Williams D, et al. Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood. 2008;111:1560–6.CrossRefPubMed Le Deley MC, Reiter A, Williams D, et al. Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood. 2008;111:1560–6.CrossRefPubMed
12.
go back to reference Gerrard M, Cairo MS, Weston C, et al. Results of the FAB LMB 96 international study in children and adolescents (C + A) with localised, resected B cell lymphoma (large cell [LCL], Burkitt’s [BL] and Burkitt-like [BLL]). Proc Am Soc Clin Oncol. 2003;22:795. Gerrard M, Cairo MS, Weston C, et al. Results of the FAB LMB 96 international study in children and adolescents (C + A) with localised, resected B cell lymphoma (large cell [LCL], Burkitt’s [BL] and Burkitt-like [BLL]). Proc Am Soc Clin Oncol. 2003;22:795.
13.
go back to reference Jayabose S, Kumar V, Dhanabalan R, Rajan P, Rathnam K, Viswanathan TK. Low-dose rasburicase in hematologic malignancies. Indian J Pediatr. 2015;82:458–61.CrossRefPubMed Jayabose S, Kumar V, Dhanabalan R, Rajan P, Rathnam K, Viswanathan TK. Low-dose rasburicase in hematologic malignancies. Indian J Pediatr. 2015;82:458–61.CrossRefPubMed
14.
go back to reference Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM group study NHL-BFM95. Blood. 2005;105:948–58.CrossRefPubMed Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM group study NHL-BFM95. Blood. 2005;105:948–58.CrossRefPubMed
15.
go back to reference Link MP, Shuster JJ, Donaldson SS, et al. Treatment of children and young adults with early-stage non-Hodgkin’s lymphoma. N Engl J Med. 1997;337:1259–66.CrossRefPubMed Link MP, Shuster JJ, Donaldson SS, et al. Treatment of children and young adults with early-stage non-Hodgkin’s lymphoma. N Engl J Med. 1997;337:1259–66.CrossRefPubMed
16.
go back to reference Arora B, Kaur U, Gulia S, et al. Modified MCP-842: a novel highly efficacious, safe and cost-effective protocol for B-NHL treatment in resource poor countries. Proceedings of the Third International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, June 2009. Frankfurt, Germany. Arora B, Kaur U, Gulia S, et al. Modified MCP-842: a novel highly efficacious, safe and cost-effective protocol for B-NHL treatment in resource poor countries. Proceedings of the Third International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, June 2009. Frankfurt, Germany.
17.
go back to reference Minard-Colin V, Auperin A, Pillon M, et al. Results of the randomized intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen [Abstract]. J Clin Oncol. 2016;34:A–10507. Minard-Colin V, Auperin A, Pillon M, et al. Results of the randomized intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen [Abstract]. J Clin Oncol. 2016;34:A–10507.
18.
go back to reference Atra A, Gerrard M, Hobson R, et al. Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin’s lymphoma treated with the UKCCSG 9003/9002 protocols. Br J Haematol. 2001;112:965–8.CrossRefPubMed Atra A, Gerrard M, Hobson R, et al. Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin’s lymphoma treated with the UKCCSG 9003/9002 protocols. Br J Haematol. 2001;112:965–8.CrossRefPubMed
19.
go back to reference Kobrinsky NL, Sposto R, Shah NR, et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin’s lymphoma and Hodgkin’s disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children’s cancer group study CCG-5912. J Clin Oncol. 2001;19:2390–6.CrossRefPubMed Kobrinsky NL, Sposto R, Shah NR, et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin’s lymphoma and Hodgkin’s disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children’s cancer group study CCG-5912. J Clin Oncol. 2001;19:2390–6.CrossRefPubMed
20.
go back to reference Griffin TC, Weitzman S, Weinstein H, et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell(CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's oncology group. Pediatr Blood Cancer. 2009;52:177–81.CrossRefPubMedPubMedCentral Griffin TC, Weitzman S, Weinstein H, et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell(CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's oncology group. Pediatr Blood Cancer. 2009;52:177–81.CrossRefPubMedPubMedCentral
21.
go back to reference Seidemann K, Tiemann M, Lauterbach I, et al. Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the berlin-Frankfurt-Munster group. J Clin Oncol. 2003;21:1782–9.CrossRefPubMed Seidemann K, Tiemann M, Lauterbach I, et al. Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the berlin-Frankfurt-Munster group. J Clin Oncol. 2003;21:1782–9.CrossRefPubMed
22.
go back to reference Gerrard M, Waxman IM, Sposto R, et al. Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy. Blood. 2013;121:278–85.CrossRefPubMedPubMedCentral Gerrard M, Waxman IM, Sposto R, et al. Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy. Blood. 2013;121:278–85.CrossRefPubMedPubMedCentral
23.
go back to reference Woessmann W, Lisfeld J, Burkhardt B, et al. Therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;369:282.CrossRefPubMed Woessmann W, Lisfeld J, Burkhardt B, et al. Therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;369:282.CrossRefPubMed
24.
go back to reference Anderson JR, Jenkin RD, Wilson JF, et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin’s lymphoma: a report of CCG-551 from the Childrens cancer group. J Clin Oncol. 1993;11:1024–32.CrossRefPubMed Anderson JR, Jenkin RD, Wilson JF, et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin’s lymphoma: a report of CCG-551 from the Childrens cancer group. J Clin Oncol. 1993;11:1024–32.CrossRefPubMed
25.
go back to reference Reiter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood. 2000;95:416–21.PubMed Reiter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood. 2000;95:416–21.PubMed
26.
go back to reference Burkhardt B, Woessmann W, Zimmermann M, et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol. 2006;24:491–9.CrossRefPubMed Burkhardt B, Woessmann W, Zimmermann M, et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol. 2006;24:491–9.CrossRefPubMed
27.
go back to reference Termuhlen AM, Smith LM, Perkins SL, et al. Outcome of newly diagnosed children and adolescents with localized lymphoblastic lymphoma treated on children’s oncology group trial A5971: a report from the children’s oncology group. Pediatr Blood Cancer. 2012;59:1229. Termuhlen AM, Smith LM, Perkins SL, et al. Outcome of newly diagnosed children and adolescents with localized lymphoblastic lymphoma treated on children’s oncology group trial A5971: a report from the children’s oncology group. Pediatr Blood Cancer. 2012;59:1229.
28.
go back to reference Termuhlen AM, Smith LM, Perkins SL, et al. Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the children's oncology group. Br J Haematol. 2013;162:792. Termuhlen AM, Smith LM, Perkins SL, et al. Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the children's oncology group. Br J Haematol. 2013;162:792.
29.
go back to reference Burkhardt B, Reiter A, Landmann E, et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the Berlin-Frankfurt-Muenster group. J Clin Oncol. 2009;27:3363–9. Burkhardt B, Reiter A, Landmann E, et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the Berlin-Frankfurt-Muenster group. J Clin Oncol. 2009;27:3363–9.
30.
go back to reference Kung FH, Harris MB, Krischer JP. Ifosfamide/carboplatin/etoposide (ICE), an effective salvaging therapy for recurrent malignant non-Hodgkin lymphoma of childhood: a pediatric oncology group phase II study. Med Pediatr Oncol. 1999;32:225–6.CrossRefPubMed Kung FH, Harris MB, Krischer JP. Ifosfamide/carboplatin/etoposide (ICE), an effective salvaging therapy for recurrent malignant non-Hodgkin lymphoma of childhood: a pediatric oncology group phase II study. Med Pediatr Oncol. 1999;32:225–6.CrossRefPubMed
31.
go back to reference Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine (compound506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's oncology group. J Clin Oncol. 2005;23:3376–82.CrossRefPubMed Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine (compound506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's oncology group. J Clin Oncol. 2005;23:3376–82.CrossRefPubMed
32.
go back to reference Kaufmann TP, Coleman M, Nisce LZ. Ki-1 skin lymphoproliferative disorders: management with radiation therapy. Cancer Investig. 1997;15:91–7.CrossRef Kaufmann TP, Coleman M, Nisce LZ. Ki-1 skin lymphoproliferative disorders: management with radiation therapy. Cancer Investig. 1997;15:91–7.CrossRef
33.
go back to reference Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol. 1996;34:470–81.CrossRefPubMed Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol. 1996;34:470–81.CrossRefPubMed
34.
go back to reference Brugières L, Le Deley MC, Rosolen A, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL group. J Clin Oncol. 2009;27:897–903.CrossRefPubMed Brugières L, Le Deley MC, Rosolen A, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL group. J Clin Oncol. 2009;27:897–903.CrossRefPubMed
35.
go back to reference Banavali SD, Arora B, Vora T, et al. Vinblastine improves outcome in children with anaplastic large cell lymphoma (ALCL) treated with a uniform short duration intensive protocol. SIOP XXXIX meeting Abstracts PJ038. Pediatr Blood Cancer. 2007;49:532. Banavali SD, Arora B, Vora T, et al. Vinblastine improves outcome in children with anaplastic large cell lymphoma (ALCL) treated with a uniform short duration intensive protocol. SIOP XXXIX meeting Abstracts PJ038. Pediatr Blood Cancer. 2007;49:532.
36.
go back to reference Laver JH, Kraveka JM, Hutchison RE, et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a pediatric oncology group phase III trial. J Clin Oncol. 2005;23:541–7.CrossRefPubMed Laver JH, Kraveka JM, Hutchison RE, et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a pediatric oncology group phase III trial. J Clin Oncol. 2005;23:541–7.CrossRefPubMed
37.
go back to reference Attarbaschi A, Dworzak M, Steiner M, et al. Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia afterintensive first-line treatment: a population-based analysis of the Austrian cooperative study group. Pediatr Blood Cancer. 2005;44:70–6.CrossRefPubMed Attarbaschi A, Dworzak M, Steiner M, et al. Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia afterintensive first-line treatment: a population-based analysis of the Austrian cooperative study group. Pediatr Blood Cancer. 2005;44:70–6.CrossRefPubMed
38.
go back to reference Woessmann W, Zimmermann M, Lenhard M, et al. Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol. 2011;29:3065–71. Woessmann W, Zimmermann M, Lenhard M, et al. Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol. 2011;29:3065–71.
39.
go back to reference Brugieres L, Pacquement H, Le Deley M-C, et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Paediatric Oncology. J Clin Oncol. 2009;27:5056–61.CrossRefPubMed Brugieres L, Pacquement H, Le Deley M-C, et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Paediatric Oncology. J Clin Oncol. 2009;27:5056–61.CrossRefPubMed
40.
go back to reference Brugières L, Quartier P, LeDeley MC, et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children--a report from the French Society of Pediatric Oncology. Ann Oncol. 2000;11:53–8.CrossRefPubMed Brugières L, Quartier P, LeDeley MC, et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children--a report from the French Society of Pediatric Oncology. Ann Oncol. 2000;11:53–8.CrossRefPubMed
41.
go back to reference Woessmann W, Peters C, Lenhard M, et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-Münster group report. Br J Haematol. 2006;133:176–82. Woessmann W, Peters C, Lenhard M, et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-Münster group report. Br J Haematol. 2006;133:176–82.
42.
go back to reference Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190–6.CrossRefPubMed Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190–6.CrossRefPubMed
43.
go back to reference Mossé YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a children's oncology group phase 1 consortium study. Lancet Oncol. 2013;14:472–80. Mossé YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a children's oncology group phase 1 consortium study. Lancet Oncol. 2013;14:472–80.
Metadata
Title
Management of Non-Hodgkin Lymphoma: ICMR Consensus Document
Authors
Nirav Thacker
Sameer Bakhshi
Girish Chinnaswamy
Tushar Vora
Maya Prasad
Deepak Bansal
Sandeep Agarwala
Gauri Kapoor
Venkatraman Radhakrishnan
Siddharth Laskar
Tanvir Kaur
G. K. Rath
Rupinder Singh Dhaliwal
Brijesh Arora
Publication date
01-05-2017
Publisher
Springer India
Published in
Indian Journal of Pediatrics / Issue 5/2017
Print ISSN: 0019-5456
Electronic ISSN: 0973-7693
DOI
https://doi.org/10.1007/s12098-017-2318-0

Other articles of this Issue 5/2017

Indian Journal of Pediatrics 5/2017 Go to the issue